Literature DB >> 9007739

Drug therapy for acquired pendular nystagmus in multiple sclerosis.

M Starck1, H Albrecht, W Pöllmann, A Straube, M Dieterich.   

Abstract

Acquired pendular nystagmus (APN) is regularly accompanied by oscillopsia and impairment of static visual acuity. Therapeutic approaches to APN remain controversial, and there is no generally accepted therapeutic approach. We tested 14 patients who had suffered from APN caused by multiple sclerosis for several years; 12 patients presented with fixational pendular nystagmus (increasing during fixation) and 2 with spontaneous pendular nystagmus. All 11 patients with fixational pendular nystagmus who were given memantine, a glutamate antagonist, experienced complete cessation of the nystagmus. In contrast, scopolamine caused no (6 of 8) or only a minor (10-50%) reduction of the nystagmus (2 of 8). It was concluded that memantine is a safe treatment option for APN.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9007739     DOI: 10.1007/pl00007728

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  26 in total

1.  Symptomatic management and rehabilitation in multiple sclerosis.

Authors:  A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

Review 2.  Medical treatment of nystagmus and its visual consequences.

Authors:  John S Stahl; Gordon T Plant; R John Leigh
Journal:  J R Soc Med       Date:  2002-05       Impact factor: 5.344

3.  Treatment of nystagmus.

Authors:  Matthew J Thurtell; R John Leigh
Journal:  Curr Treat Options Neurol       Date:  2012-02       Impact factor: 3.598

4.  Acquired Nystagmus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

Review 5.  What we know about the generation of nystagmus and other ocular oscillations: are we closer to identifying therapeutic targets?

Authors:  Rebecca Jane McLean; Irene Gottlob; Frank Antony Proudlock
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

6.  Crossover trial of gabapentin and memantine as treatment for acquired nystagmus.

Authors:  Matthew J Thurtell; Anand C Joshi; Alice C Leone; Robert L Tomsak; Gregory S Kosmorsky; John S Stahl; R John Leigh
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

7.  Current treatment of vestibular, ocular motor disorders and nystagmus.

Authors:  Michael Strupp; Thomas Brandt
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

8.  Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.

Authors:  Stefania Maraka; Morris D Groves; Aaron G Mammoser; Isaac Melguizo-Gavilanes; Charles A Conrad; Ivo W Tremont-Lukats; Monica E Loghin; Barbara J O'Brien; Vinay K Puduvalli; Erik P Sulman; Kenneth R Hess; Kenneth D Aldape; Mark R Gilbert; John F de Groot; W K Alfred Yung; Marta Penas-Prado
Journal:  Cancer       Date:  2018-10-25       Impact factor: 6.860

9.  Neuro-ophthalmologic aspects of multiple sclerosis: Using eye movements as a clinical and experimental tool.

Authors:  Annette Niestroy; Janet C Rucker; R John Leigh
Journal:  Clin Ophthalmol       Date:  2007-09

10.  Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin.

Authors:  Michaela Starck; Holger Albrecht; Walter Pöllmann; Marianne Dieterich; Andreas Straube
Journal:  J Neurol       Date:  2009-09-13       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.